The UK regulator is creating a new framework for how it will approve rare disease treatments, which it intends to publish in ...

Genetic testing could improve cancer outcomes for patients, but historical research abuses and access issues have slowed ...

AstraZeneca's net profit in Q3 2025 was $2.54 billion, or $1.64 per share, compared to $1.43 billion, or $.92 per share, in Q3 2024. The firm beat the Wall Street consensus EPS estimate of $1.13.

Under the agreement, Singapore-headquartered ImmunoScape will develop what it calls a "Seed-and-Boost" immunotherapy, combining its T-cell receptor therapies (the "seed") followed by Cue's IL-2-based ...

DMT in recent months has focused resources on developing its lead gene therapy candidate 4D-150 in wet age-related macular degeneration.

The funding is to go toward the launch of the Elephas Live Platform as a laboratory-developed test to predict immunotherapy response.

The agency is establishing a network of care centers to expand access to regenerative medicine beyond regions served by major ...

The firm had decreased Q3 sales for precision oncology drugs including Ibrance, Tukysa, and Bosulif, but sales increased for ...

Researchers presented new data on Phenomix Sciences' genetic risk scores at the Obesity Society's ObesityWeek conference.

Atara transferred the BLA to Pierre Fabre, which already handles manufacturing, regulatory, and commercial activities for Ebvallo in Europe.

Sales of the leukemia drug Blincyto grew 20 percent to $392 million, but Lumakras sales decreased 2 percent to $96 million, compared to Q3 2024.

The firm will use proceeds to complete clinical proof of concept of its lead gene therapy programs in rare, inherited retinal diseases.